Second Clinical Medical College, Zhejiang Chinese Medical University, Zhejiang, China.
College of Medical Technology, Zhejiang Chinese Medical University, Zhejiang, China.
Pharmazie. 2021 Sep 1;76(9):404-411. doi: 10.1691/ph.2021.1524.
According to the latest statistics from WHO for all cancers, lung cancer tops the list with a 14.5% prevalence and a 22% death rate in men, similar to the prevalence in women, which is 13.8%. It is also the number one killer of cancer in China, with 40 in every 100,000 people suffering from lung cancer. HIF-1α is widely present in human cells in hypoxic environments. It regulates the body's response to hypoxia, cell oxygen balance, and hypoxia gene expression; participates in the proliferation and apoptosis of non-small cell lung cancer cells; participates in the invasion, metastasis, and neovascularization of tumor tissues; and affects the treatment and prognosis of non-small cell lung cancer. In view of the role of HIF-1α in the occurrence and development of non-small cell lung cancer, blocking HIF-1α by use of a single medication or combination chemotherapy has become a research hotspot. This review summarizes the role of HIF-1α in non-small cell lung cancer and provides new ideas for the treatment of this cancer type by synthesizing the research results of various authors.
根据世卫组织发布的所有癌症最新统计数据，肺癌在男性中的发病率为 14.5%，死亡率为 22%，与女性的发病率（13.8%）相似。它也是中国癌症的头号杀手，每 10 万人中就有 40 人患有肺癌。HIF-1α 在缺氧环境中广泛存在于人体细胞中。它调节机体对缺氧的反应、细胞氧平衡和缺氧基因表达；参与非小细胞肺癌细胞的增殖和凋亡；参与肿瘤组织的侵袭、转移和新生血管形成；并影响非小细胞肺癌的治疗和预后。鉴于 HIF-1α 在非小细胞肺癌发生发展中的作用，通过单一药物或联合化疗阻断 HIF-1α 已成为研究热点。本综述总结了 HIF-1α 在非小细胞肺癌中的作用，并综合了各作者的研究结果，为该类型癌症的治疗提供了新的思路。
